The purpose of this study is to determine the safety and efficacy of Zilretta (FX006) in bursal injections and to assess the patient's impression to change in treatments, to their chronic pain.
- Study Type: Interventional
- Study Design
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: July 6, 2020
- Drug: Zilretta
- Subjects will be injected with the 5ml of FX006. This injection may be followed with up to 3ml of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
Arms, Groups and Cohorts
- Experimental: Zilretta
Clinical Trial Outcome Measures
- Change in pain from baseline as assessed by the Numeric Pain Rating Scale (NPRS) score
- Time Frame: Baseline,week 12
- Numeric Pain Rating Scale total score ranges from 0 (no pain) to 10 (most intense pain imaginable).
- Change in patient’s impression to change in treatment,to their chronic pain as measured by the Patient Global Impression of Change (PGIC) measure
- Time Frame: Baseline,week 12
- The PGIC is a 7 point scale ranging from very much improved (1) to very much worsened (7)
Participating in This Clinical Trial
- Written consent to participate in the study
- Symptoms consistent with greater trochanteric bursitis for greater than or equal to 3 months prior to screening (patient reported is acceptable)
- Pain in hip for greater than 15 days over the last month (as reported by the patient).
- Hip bursitis as determined by clinical examination and clinical features. Where Magnetic Resonance Imaging (MRI) data is available, it will be used to confirm the bursitis diagnosis. Also, pain relief in subjects that have been treated with bursal injections containing an anesthetic (such as ropivacaine) is in itself indicative of bursitis.
- Body mass index (BMI) less than or equal to 40 kg/m2
- Ambulatory and in good general health
- Willing and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.
- Willing to abstain from use of protocol-restricted medications during the study
- Hip Arthroplasty
- Hip osteoarthritis, iliopsoas bursitis, reactive arthritis,rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
- History of local infection around the bursa.
- Lack of pain relief with the intrabursal treatments containing an anesthetic
- Intra-bursal treatment of any bursa with any of the following agents within six (6) months of screening:any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g.,platelet rich plasma (PRP) injection, stem cells,prolotherapy, amniotic fluid injection; investigational or marketed).
- Parenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening <0000> Inhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of screening.
- Females who are pregnant or nursing or plan to become pregnant during the study; women who plan to conceive
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- The University of Texas Health Science Center, Houston
- Flexion Therapeutics, Inc.
- Provider of Information About this Clinical Study
- Principal Investigator: Pritish Bawa, Assistant Professor – The University of Texas Health Science Center, Houston
- Overall Official(s)
- Pritish Bawa, MD, Principal Investigator, The University of Texas Health Science Center, Houston
- Overall Contact(s)
- Pritish Bawa, MD, 713-500-7706, Pritish.email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.